Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

26.11 +0.22 (+0.85%)
Streaming Delayed Price Updated: 10:38 AM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Positive Technical Setup ↗
Catalyst Pharmaceuticals (CPRX) combines strong growth, high profitability, and a debt-free balance sheet with a positive technical trend, signaling a potential breakout opportunity. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock ↗
Catalyst Pharmaceuticals (CPRX) exemplifies affordable growth with strong earnings, a debt-free balance sheet, and a valuation below industry averages. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment ↗
Via Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup ↗
Via Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout ↗
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Beats Q4 Estimates, Issues Conservative 2026 Outlook ↗
Via Chartmill
News headline image
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup ↗
Via Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Screens as an Affordable Growth Stock ↗
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. 
Via The Motley Fool
Topics ETFs Intellectual Property World Trade
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Fundamentals with a Technical Breakout Setup ↗
Via Chartmill
News headline image
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? ↗
The exercise-and-sell transaction came as the rare disease drugmaker reported strong quarterly results. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Stock Pick ↗
Catalyst Pharmaceuticals (CPRX) exemplifies the GARP strategy with strong growth, high profitability, and a reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Bullish Technical Setup ↗
Catalyst Pharmaceuticals (CPRX) combines strong growth fundamentals with a bullish technical setup, offering a rare biotech investment opportunity. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes the Caviar Cruise Quality Investing Screen ↗
Catalyst Pharmaceuticals exemplifies quality investing with high growth, exceptional profitability, a debt-free balance sheet, and an attractive valuation. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Represents an Affordable Growth Opportunity ↗
Catalyst Pharmaceuticals offers strong growth, solid profitability, and a debt-free balance sheet, all at an attractive valuation compared to its biotech peers. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup ↗
Discover Catalyst Pharmaceuticals (CPRX), a growth stock with strong earnings and a bullish technical breakout pattern, signaling potential upside. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™
Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment on Caviar Cruise Screen ↗
Catalyst Pharmaceuticals is a high-quality growth stock with exceptional profitability, zero debt, and strong cash flow, making it a standout in the biotech sector. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.